Alfredo Mendrone-Junior
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Alfredo Mendrone-Junior has a total of 150 co-authors. Here are the top co-authors by number of shared publications:
- Cesar de Almeida-Neto
Division of Research & Transfusion Medicine Pro‐Blood Foundation/Blood Center of São Paulo São Paulo Brazil
12 shared publications - Vanderson Rocha
Serviço de Hematologia, Hemoterapia e Terapia Celular, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo 05403-000, Brazil
11 shared publications - Anna Shoko Nishiya
Fundação Pró‐Sangue Hemocentro de São Paulo São Paulo Brazil
10 shared publications - Suzete Cleusa Ferreira
Fundação Pró‐Sangue Hemocentro de São Paulo São Paulo Brazil
10 shared publications - Ester Cerdeira Sabino
Faculdade de Medicina (FMUSP) and Instituto de Medicina Tropical, Universidade de São Paulo, São Paulo, Brazil
9 shared publications - Nanci Alves Salles
Fundação Pró-Sangue Hemocentro de São Paulo, São Paulo 05403-000, Brazil
6 shared publications
Latest Publications
- Open Access
- 11 November 2026
- Published by Wiley in Vox Sanguinis
Digital connectivity in plateletpheresis collections improves productivity and workflow efficiency without compromising donor safety
Background and Objectives: Blood banks face pressure to meet the growing demand for platelet components while improving operational efficiency and maintaining donor and patient safety. This study describes a data‐driven strategy using connectivity tools to reduce data transfer errors, optimize workflow, and safely implement high‐yield platelet collections. Materials and Methods: This retrospective observational study analyzed plateletpheresis procedures performed with Trima Accel™ Automated Blood Collection System between January 2022 and November 2025 at Fundação Pró‐Sangue, São Paulo. In November 2022, the Terumo Operational Medical Equipment Software (TOMEs™) middleware was implemented to establish a bidirectional interface between apheresis devices and the blood bank information system. Data‐driven simulations identified donors eligible for high‐yield collections, enabling the introduction of triple‐dose plateletpheresis in October 2024. Variables included donor data discrepancies, adverse events, procedure duration, platelet yield, predicted post‐procedure platelet counts, anticoagulant use, inter‐donation intervals, and workflow efficiency. Outcomes before and after implementation were compared. Results: Integration of the bidirectional interface reduced donor data discrepancies from 47% to 3%, and decreased manual interactions by 30%, improving data reliability and operational efficiency. Simulations showed that 30% of donors met Brazilian regulatory criteria for triple‐dose plateletpheresis. After implementation, plateletpheresis productivity increased 16%. Adverse event rates remained low and comparable before and after implementation (8.2% vs. 7.9%). Predicted post‐procedure platelet counts in triple donors remained within the device safety threshold recommended by Brazilian policies. Conclusion: Digital integration and data‐driven decision‐making enable the safe implementation of triple‐dose plateletpheresis, improving productivity without compromising donor safety. This approach may serve as a practical model for blood centers, particularly in resource‐limited settings.
- 11 November 2026
- Published by Wiley in Vox Sanguinis
Open AccessDigital connectivity in plateletpheresis collections improves productivity and workflow efficiency without compromising donor safety
Background and Objectives: Blood banks face pressure to meet the growing demand for platelet components while improving operational efficiency and maintaining donor and patient safety. This study describes a data‐driven strategy using connectivity tools to reduce data transfer errors, optimize workflow, and safely implement high‐yield platelet collections. Materials and Methods: This retrospective observational study analyzed plateletpheresis procedures performed with Trima Accel™ Automated Blood Collection System between January 2022 and November 2025 at Fundação Pró‐Sangue, São Paulo. In November 2022, the Terumo Operational Medical Equipment Software (TOMEs™) middleware was implemented to establish a bidirectional interface between apheresis devices and the blood bank information system. Data‐driven simulations identified donors eligible for high‐yield collections, enabling the introduction of triple‐dose plateletpheresis in October 2024. Variables included donor data discrepancies, adverse events, procedure duration, platelet yield, predicted post‐procedure platelet counts, anticoagulant use, inter‐donation intervals, and workflow efficiency. Outcomes before and after implementation were compared. Results: Integration of the bidirectional interface reduced donor data discrepancies from 47% to 3%, and decreased manual interactions by 30%, improving data reliability and operational efficiency. Simulations showed that 30% of donors met Brazilian regulatory criteria for triple‐dose plateletpheresis. After implementation, plateletpheresis productivity increased 16%. Adverse event rates remained low and comparable before and after implementation (8.2% vs. 7.9%). Predicted post‐procedure platelet counts in triple donors remained within the device safety threshold recommended by Brazilian policies. Conclusion: Digital integration and data‐driven decision‐making enable the safe implementation of triple‐dose plateletpheresis, improving productivity without compromising donor safety. This approach may serve as a practical model for blood centers, particularly in resource‐limited settings.
- 28 July 2026
- Published by Wiley in Journal of Viral Hepatitis
- Vol. 33 (8)
Absence of Detectable Anti‐ HDV Antibodies Among HBsAg ‐Positive Blood Donors, HIV ‐Infected Individuals and Patients With Chronic Hepatitis B in Sao Paulo, Brazil: Evaluation Using a Rapid Lateral Flow Assay
Hepatitis Delta Virus (HDV) infection in HBV‐infected individuals is associated with severe clinical outcomes, and screening is recommended in HBsAg‐positive patients. We used a rapid lateral flow assay (LFA) to assess anti‐HDV antibodies in Brazil, where HDV is highly endemic in the North, while data from the Southeast, particularly São Paulo, remain limited. We conducted a retrospective cross‐sectional study to assess anti‐HDV antibodies among 46 HBsAg‐positive blood donors at Fundação Pró‐Sangue/Hemocentro de São Paulo, 381 patients with chronic hepatitis B from the Central Laboratory Division of HC‐FMUSP, and 189 individuals from the Hepatology Clinic of HC‐FMUSP (101 HIV‐infected and 88 chronically HBV‐infected). Anti‐HDV antibodies were detected using a validated LFA. Positive controls ( n = 24) included samples previously confirmed by ELISA and/or PCR, predominantly infected with HDV genotypes 3 and 8. Among 443,400 blood donations, 48 (0.01%) were positive for at least two HBV markers; of these, 46 were tested for HDV, and all were anti‐HDV negative. All 381 patients undergoing HBV viral load monitoring were anti‐HDV negative, as were all 189 patients receiving hepatology care, including those with HIV coinfection or advanced liver disease. The LFA correctly identified all control samples positive for both anti‐HDV antibodies and HDV RNA. The absence of detectable anti‐HDV among diverse at‐risk populations in São Paulo is consistent with the low endemicity of HDV infection in southeastern Brazil. These findings, together with the assay's high specificity in HDV RNA‐positive controls, support its potential utility as a screening tool for HDV infection in low‐prevalence settings.
- 28 July 2026
- Published by Wiley in Journal of Viral Hepatitis
- Vol. 33 (8)
Absence of Detectable Anti‐ HDV Antibodies Among HBsAg ‐Positive Blood Donors, HIV ‐Infected Individuals and Patients With Chronic Hepatitis B in Sao Paulo, Brazil: Evaluation Using a Rapid Lateral Flow Assay
Hepatitis Delta Virus (HDV) infection in HBV‐infected individuals is associated with severe clinical outcomes, and screening is recommended in HBsAg‐positive patients. We used a rapid lateral flow assay (LFA) to assess anti‐HDV antibodies in Brazil, where HDV is highly endemic in the North, while data from the Southeast, particularly São Paulo, remain limited. We conducted a retrospective cross‐sectional study to assess anti‐HDV antibodies among 46 HBsAg‐positive blood donors at Fundação Pró‐Sangue/Hemocentro de São Paulo, 381 patients with chronic hepatitis B from the Central Laboratory Division of HC‐FMUSP, and 189 individuals from the Hepatology Clinic of HC‐FMUSP (101 HIV‐infected and 88 chronically HBV‐infected). Anti‐HDV antibodies were detected using a validated LFA. Positive controls ( n = 24) included samples previously confirmed by ELISA and/or PCR, predominantly infected with HDV genotypes 3 and 8. Among 443,400 blood donations, 48 (0.01%) were positive for at least two HBV markers; of these, 46 were tested for HDV, and all were anti‐HDV negative. All 381 patients undergoing HBV viral load monitoring were anti‐HDV negative, as were all 189 patients receiving hepatology care, including those with HIV coinfection or advanced liver disease. The LFA correctly identified all control samples positive for both anti‐HDV antibodies and HDV RNA. The absence of detectable anti‐HDV among diverse at‐risk populations in São Paulo is consistent with the low endemicity of HDV infection in southeastern Brazil. These findings, together with the assay's high specificity in HDV RNA‐positive controls, support its potential utility as a screening tool for HDV infection in low‐prevalence settings.
- 5 May 2026
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 83 (2) , 234-238
Fatal Transfusion-transmitted Severe Dengue in an Immunocompromised Host: Case Report and Systematic Literature Review
Transfusion-transmitted dengue remains a relevant risk during outbreaks. We report a transfusion-transmitted severe dengue case in a stem cell transplant recipient during the 2024 epidemic in Brazil, supported by phylogenetic linkage, evolving to a fatal outcome. This sentinel case highlights the potential severity of transfusion-transmitted dengue, particularly in immunocompromised hosts.
- 5 May 2026
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 83 (2) , 234-238
Fatal Transfusion-transmitted Severe Dengue in an Immunocompromised Host: Case Report and Systematic Literature Review
Transfusion-transmitted dengue remains a relevant risk during outbreaks. We report a transfusion-transmitted severe dengue case in a stem cell transplant recipient during the 2024 epidemic in Brazil, supported by phylogenetic linkage, evolving to a fatal outcome. This sentinel case highlights the potential severity of transfusion-transmitted dengue, particularly in immunocompromised hosts.
- Open Access
- 7 July 2025
- Vol. 67, e44
Osteomyelitis and aortic arteritis with thrombosis as primary manifestations of severe paracoccidioidomycosis: a case report.
Paracoccidioidomycosis (PCM) configures a deep mycosis caused by Paracoccidioides spp., a neglected tropical disease. We describe a fatal case of PCM that manifested itself as osteomyelitis with thrombosis in the iliac artery in a man with frequent contact with an endemic region in Sao Paulo, Brazil. A 67-year-old man living in an endemic area presented with osteomyelitis of the femur and iliac artery thrombosis on admission to the hospital. Computed tomography of the chest showed multiple cavitated pulmonary nodules. The patient rapidly progressed to irreversible respiratory failure. The autopsy showed disseminated PCM and iliac artery thrombosis. Laboratory investigation confirmed P. brasiliensis infection with a strain identified in Sao Paulo as P. brasiliensis complex by phylogenetic analysis. Atypical PCM remains a diagnostic challenge. Increased awareness of the sites of infection and its clinical presentations will improve patient management.
- 7 July 2025
- Vol. 67, e44
Open AccessOsteomyelitis and aortic arteritis with thrombosis as primary manifestations of severe paracoccidioidomycosis: a case report.
Paracoccidioidomycosis (PCM) configures a deep mycosis caused by Paracoccidioides spp., a neglected tropical disease. We describe a fatal case of PCM that manifested itself as osteomyelitis with thrombosis in the iliac artery in a man with frequent contact with an endemic region in Sao Paulo, Brazil. A 67-year-old man living in an endemic area presented with osteomyelitis of the femur and iliac artery thrombosis on admission to the hospital. Computed tomography of the chest showed multiple cavitated pulmonary nodules. The patient rapidly progressed to irreversible respiratory failure. The autopsy showed disseminated PCM and iliac artery thrombosis. Laboratory investigation confirmed P. brasiliensis infection with a strain identified in Sao Paulo as P. brasiliensis complex by phylogenetic analysis. Atypical PCM remains a diagnostic challenge. Increased awareness of the sites of infection and its clinical presentations will improve patient management.
- Open Access
- 1 January 2024
- Published by FapUNIFESP (SciELO) in Revista do Instituto de Medicina Tropical de São Paulo
- Vol. 66, e35
Genetic diversity in the partial sequence of the HIV-1 gag gene among people living with multidrug-resistant HIV-1 infection
The group-specific antigen (gag) plays a crucial role in the assembly, release, and maturation of HIV. This study aimed to analyze the partial sequence of the HIV gag gene to classify HIV subtypes, identify recombination sites, and detect protease inhibitor (PI) resistance-associated mutations (RAMs). The cohort included 100 people living with HIV (PLH) who had experienced antiretroviral treatment failure with reverse transcriptase/protease inhibitors. Proviral HIV-DNA was successfully sequenced in 96 out of 100 samples for gag regions, specifically matrix (p17) and capsid (p24). Moreover, from these 96 sequences, 82 (85.42%) were classified as subtype B, six (6.25%) as subtype F1, one (1.04%) as subtype C, and seven (7.29%) exhibited a mosaic pattern between subtypes B and F1 (B/F1), with breakpoints at p24 protein. Insertions and deletions of amino acid at p17 were observed in 51 samples (53.13%). The prevalence of PI RAM in the partial gag gene was observed in 78 out of 96 PLH (81.25%). Among these cases, the most common mutations were R76K (53.13%), Y79F (31.25%), and H219Q (14.58%) at non-cleavage sites, as well as V128I (10.42%) and Y132F (11.46%) at cleavage sites. While B/F1 recombination was identified in the p24, the p17 coding region showed higher diversity, where insertions, deletions, and PI RAM, were observed at high prevalence. In PLH with virological failure, the analysis of the partial gag gene could contribute to more accurate predictions in genotypic resistance to PIs. This can aid guide more effective HIV treatment strategies.
- 1 January 2024
- Published by FapUNIFESP (SciELO) in Revista do Instituto de Medicina Tropical de São Paulo
- Vol. 66, e35
Open AccessGenetic diversity in the partial sequence of the HIV-1 gag gene among people living with multidrug-resistant HIV-1 infection
The group-specific antigen (gag) plays a crucial role in the assembly, release, and maturation of HIV. This study aimed to analyze the partial sequence of the HIV gag gene to classify HIV subtypes, identify recombination sites, and detect protease inhibitor (PI) resistance-associated mutations (RAMs). The cohort included 100 people living with HIV (PLH) who had experienced antiretroviral treatment failure with reverse transcriptase/protease inhibitors. Proviral HIV-DNA was successfully sequenced in 96 out of 100 samples for gag regions, specifically matrix (p17) and capsid (p24). Moreover, from these 96 sequences, 82 (85.42%) were classified as subtype B, six (6.25%) as subtype F1, one (1.04%) as subtype C, and seven (7.29%) exhibited a mosaic pattern between subtypes B and F1 (B/F1), with breakpoints at p24 protein. Insertions and deletions of amino acid at p17 were observed in 51 samples (53.13%). The prevalence of PI RAM in the partial gag gene was observed in 78 out of 96 PLH (81.25%). Among these cases, the most common mutations were R76K (53.13%), Y79F (31.25%), and H219Q (14.58%) at non-cleavage sites, as well as V128I (10.42%) and Y132F (11.46%) at cleavage sites. While B/F1 recombination was identified in the p24, the p17 coding region showed higher diversity, where insertions, deletions, and PI RAM, were observed at high prevalence. In PLH with virological failure, the analysis of the partial gag gene could contribute to more accurate predictions in genotypic resistance to PIs. This can aid guide more effective HIV treatment strategies.
- Open Access
- 1 January 2024
- Published by FapUNIFESP (SciELO) in Revista do Instituto de Medicina Tropical de São Paulo
- Vol. 66, e11
Prevalence and clinical consequences of Hepatitis C virus infection in patients undergoing hematopoietic stem cell transplantation
Hepatitis C virus (HCV) infection is a significant cause of morbidity and mortality among hematopoietic stem cell transplant (HCT) recipients. In Brazil, its occurrence in HCT recipients remains undetermined. We now report on HCV prevalence in HCT recipients and its clinical consequences. The medical records of all HCT recipients seen at Hospital das Clinicas, Sao Paulo University Medical School, from January 2010 to January 2020 were reviewed to determine HCV serostatus. A retrospective analysis of medical charts was undertaken on all seropositive cases to determine HCV genotype, presence of liver fibrosis, co-infections with other viruses, previous treatments, and clinical evolution of liver pathology after HCT. Of the 1,293 HCT recipients included in the study, seven (0.54%) were HCV antibody-positive and five (0.39%) were also viremic for HCV-RNA. Four of these individuals had moderate to severe liver fibrosis (METAVIR F2/F3) and one was cirrhotic. Two of the viremic patients developed acute liver dysfunction following transplantation. All patients had their acute episode of liver dysfunction resolved with no further complications. Four of the viremic patients were treated for HCV infection with direct acting agents (DAA). Information regarding HCV treatment was lacking for one of the viremic HCV patients due to loss of follow up. Sustained anti-virologic responses were observed in three cases after the use of DAA. The detection of HCV in hematological adults undergoing HCT and its successful treatment with DAA highlight the necessity of testing for HCV both prior to and following transplantation.
- 1 January 2024
- Published by FapUNIFESP (SciELO) in Revista do Instituto de Medicina Tropical de São Paulo
- Vol. 66, e11
Open AccessPrevalence and clinical consequences of Hepatitis C virus infection in patients undergoing hematopoietic stem cell transplantation
Hepatitis C virus (HCV) infection is a significant cause of morbidity and mortality among hematopoietic stem cell transplant (HCT) recipients. In Brazil, its occurrence in HCT recipients remains undetermined. We now report on HCV prevalence in HCT recipients and its clinical consequences. The medical records of all HCT recipients seen at Hospital das Clinicas, Sao Paulo University Medical School, from January 2010 to January 2020 were reviewed to determine HCV serostatus. A retrospective analysis of medical charts was undertaken on all seropositive cases to determine HCV genotype, presence of liver fibrosis, co-infections with other viruses, previous treatments, and clinical evolution of liver pathology after HCT. Of the 1,293 HCT recipients included in the study, seven (0.54%) were HCV antibody-positive and five (0.39%) were also viremic for HCV-RNA. Four of these individuals had moderate to severe liver fibrosis (METAVIR F2/F3) and one was cirrhotic. Two of the viremic patients developed acute liver dysfunction following transplantation. All patients had their acute episode of liver dysfunction resolved with no further complications. Four of the viremic patients were treated for HCV infection with direct acting agents (DAA). Information regarding HCV treatment was lacking for one of the viremic HCV patients due to loss of follow up. Sustained anti-virologic responses were observed in three cases after the use of DAA. The detection of HCV in hematological adults undergoing HCT and its successful treatment with DAA highlight the necessity of testing for HCV both prior to and following transplantation.
- 13 September 2023
- Published by Wiley in Transfusion
- Vol. 63 (11) , 2106-2113
Detection of unreported usage of the antiretroviral drug lamivudine in two blood donors
Background: Unreported HIV antiretroviral (ARV) drug usage by blood donors compromises the ability to detect evidence of HIV infection in blood screening tests and represents a risk for blood transfusion safety. Our objective was to determine the frequency of undeclared ARV drug use by blood donors with altered HIV markers.Study Design and Methods: This was a retrospective cross‐sectional analysis of donations that were tested for HIV antibody (ab), antigen (ag), and RNA by chemiluminescent immunoassay and nucleic acid screening tests. Positive samples were retested and were subjected to ARV drug testing by high‐performance liquid chromatography–tandem mass spectrometry.Results: Of 345,252 blood donations, 361 (0.1%) were positive on initial testing. Samples from 296 (81.9%) of these donations were available for further analysis. The presence of HIV ab/ag and/or RNA was confirmed in 83 (28.0%) of these samples. All 296 bloods were subjected to ARV testing. The ARV drug lamivudine, at 11.3 and 6.7 ng/mL, was detected in 2 of 83 (2.4%) donations that were HIV positive. Other drugs were not detected.Conclusion: Unreported ARV usage was identified in two candidates for blood donation. More intensive efforts to educate donors about disclosure and to investigate the extent of this phenomenon in Brazil are needed.
- 13 September 2023
- Published by Wiley in Transfusion
- Vol. 63 (11) , 2106-2113
Detection of unreported usage of the antiretroviral drug lamivudine in two blood donors
Background: Unreported HIV antiretroviral (ARV) drug usage by blood donors compromises the ability to detect evidence of HIV infection in blood screening tests and represents a risk for blood transfusion safety. Our objective was to determine the frequency of undeclared ARV drug use by blood donors with altered HIV markers.Study Design and Methods: This was a retrospective cross‐sectional analysis of donations that were tested for HIV antibody (ab), antigen (ag), and RNA by chemiluminescent immunoassay and nucleic acid screening tests. Positive samples were retested and were subjected to ARV drug testing by high‐performance liquid chromatography–tandem mass spectrometry.Results: Of 345,252 blood donations, 361 (0.1%) were positive on initial testing. Samples from 296 (81.9%) of these donations were available for further analysis. The presence of HIV ab/ag and/or RNA was confirmed in 83 (28.0%) of these samples. All 296 bloods were subjected to ARV testing. The ARV drug lamivudine, at 11.3 and 6.7 ng/mL, was detected in 2 of 83 (2.4%) donations that were HIV positive. Other drugs were not detected.Conclusion: Unreported ARV usage was identified in two candidates for blood donation. More intensive efforts to educate donors about disclosure and to investigate the extent of this phenomenon in Brazil are needed.
- 17 October 2022
- Published by Wiley in Transfusion Medicine
- Vol. 33 (2) , 159-164
Improved detection of hepatitis C virus‐positive blood donors and determination of infection status
Background: In low‐risk populations, variability in the sensitivity of current serological tests for Hepatitis C virus (HCV) blood donor screening may lead to the presence of false‐positive results. This contributes to the unnecessary loss of blood donor samples as well as to difficulty in accurate donor counselling. The present study determined the optimal cut‐off value of a chemiluminescent immunoassay for identification of HCV‐reactive blood donors.Study Design and Methods: In a retrospective cross‐sectional analysis of 193 973 blood donations, 578 samples that were positive for HCV antibody in a chemiluminescent immunoassay and/or RNA screening tests were identified. Blood from 379 of these positive samples was available for retesting by a second confirmatory HCV immunoassay followed by a receiver operating characteristic (ROC) curve analysis. Donors were also recalled for a new analysis.Results: Only 71 (18.7%) blood samples remained HCV‐positive upon retesting, while 233 (61.5%) now tested negative and 75 (19.8%) yielding indeterminate results. A signal to cutoff ratio ≥4.32 was determined as the best differential threshold between a positive and negative result, increasing the positive predictive value from 27.3% to 66.7%.Conclusion: Using a higher threshold for an HCV‐positive blood sample enhances the chemiluminescent immunoassay screening test´s accuracy and helps to improve donor counselling and notification processes.
- 17 October 2022
- Published by Wiley in Transfusion Medicine
- Vol. 33 (2) , 159-164
Improved detection of hepatitis C virus‐positive blood donors and determination of infection status
Background: In low‐risk populations, variability in the sensitivity of current serological tests for Hepatitis C virus (HCV) blood donor screening may lead to the presence of false‐positive results. This contributes to the unnecessary loss of blood donor samples as well as to difficulty in accurate donor counselling. The present study determined the optimal cut‐off value of a chemiluminescent immunoassay for identification of HCV‐reactive blood donors.Study Design and Methods: In a retrospective cross‐sectional analysis of 193 973 blood donations, 578 samples that were positive for HCV antibody in a chemiluminescent immunoassay and/or RNA screening tests were identified. Blood from 379 of these positive samples was available for retesting by a second confirmatory HCV immunoassay followed by a receiver operating characteristic (ROC) curve analysis. Donors were also recalled for a new analysis.Results: Only 71 (18.7%) blood samples remained HCV‐positive upon retesting, while 233 (61.5%) now tested negative and 75 (19.8%) yielding indeterminate results. A signal to cutoff ratio ≥4.32 was determined as the best differential threshold between a positive and negative result, increasing the positive predictive value from 27.3% to 66.7%.Conclusion: Using a higher threshold for an HCV‐positive blood sample enhances the chemiluminescent immunoassay screening test´s accuracy and helps to improve donor counselling and notification processes.
- Open Access
Transfusion-Acquired HIV: History, Evolution of Screening Tests, and Current Challenges of Unreported Antiretroviral Drug Use in Brazil
Prevention of HIV acquisition by blood transfusion from its emergence to the present day is reviewed, and current challenges are delineated. The experience of Fundação Pró-Sangue/Hemocentro de São Paulo, Brazil, is highlighted in the quest for improvements in blood safety and the evolution of increasingly sensitive and specific screening tests. Concerns and establishing stringent criteria in the screening of potential blood donors are emphasized, and the current criteria for identifying and deferring candidates at high risk of acquiring sexually transmitted diseases are summarized. Future challenges relate to the identification of donors with unreported use of antiretroviral drugs for prophylaxis against possible HIV exposure or for treatment of an HIV infection whose viral expression is undetectable by current analyses. There is a need to better understand the motivation of HIV-exposed donors and to educate them about the risk of transfusion-mediated HIV transmission despite having low or undetectable viral loads. In situations in which traditional HIV RNA or antibody detection assays remain negative, more sensitive analyses are needed to identify potential donors at risk for HIV transmission.
Open AccessTransfusion-Acquired HIV: History, Evolution of Screening Tests, and Current Challenges of Unreported Antiretroviral Drug Use in Brazil
Prevention of HIV acquisition by blood transfusion from its emergence to the present day is reviewed, and current challenges are delineated. The experience of Fundação Pró-Sangue/Hemocentro de São Paulo, Brazil, is highlighted in the quest for improvements in blood safety and the evolution of increasingly sensitive and specific screening tests. Concerns and establishing stringent criteria in the screening of potential blood donors are emphasized, and the current criteria for identifying and deferring candidates at high risk of acquiring sexually transmitted diseases are summarized. Future challenges relate to the identification of donors with unreported use of antiretroviral drugs for prophylaxis against possible HIV exposure or for treatment of an HIV infection whose viral expression is undetectable by current analyses. There is a need to better understand the motivation of HIV-exposed donors and to educate them about the risk of transfusion-mediated HIV transmission despite having low or undetectable viral loads. In situations in which traditional HIV RNA or antibody detection assays remain negative, more sensitive analyses are needed to identify potential donors at risk for HIV transmission.
- Open Access
- 19 January 2022
- Published by Elsevier in Hematology, Transfusion and Cell Therapy
- Vol. 44 (2) , 206-212
Development and implementation of a COVID-19 convalescent plasma program in a middle-income economy
- 19 January 2022
- Published by Elsevier in Hematology, Transfusion and Cell Therapy
- Vol. 44 (2) , 206-212
Open AccessDevelopment and implementation of a COVID-19 convalescent plasma program in a middle-income economy